Syntex' nafarelin
Executive Summary
NDA for the treatment of endometriosis is expected to be filed by the end of the company's current fiscal year (July 31), Syntex Chairman Albert Bowers told analysts in New York Jan. 18. Bowers also noted that the company has four NDAs pending at the agency, including Cardene, Ticlid, Gardrin and Toradol. The injectable pain killer Toradol (ketorolac) has been given a 1-B rating by the agency, Bowers said.
NDA for the treatment of endometriosis is expected to be filed by
the end of the company's current fiscal year (July 31), Syntex
Chairman Albert Bowers told analysts in New York Jan. 18. Bowers
also noted that the company has four NDAs pending at the agency,
including Cardene, Ticlid, Gardrin and Toradol. The
injectable pain killer Toradol (ketorolac) has been given a 1-B
rating by the agency, Bowers said. |